Trial Outcomes & Findings for In Clinic Optometrist Insertion of Dextenza Prior to Cataract Surgery (NCT NCT05023304)
NCT ID: NCT05023304
Last Updated: 2025-08-17
Results Overview
Mean anterior chamber cell/flare score measured by Slit Lamp Biomicroscopy evaluation using grading scale of 0 to 4 +. The scale used is called the (Standardization of Uveitis Nomenclature) SUN Working Group Grading Scheme. AC cell grading schema. The SUN Working Group defined their two AC grading schemas around these two findings. Importantly, for all grading schemas discussed in this article, an improvement in inflammation is a two-step decrease in grade. A worsening of inflammation occurs with a two-step increase in grade. Grade 0 = 0 cells per high power field or HPF; Grade 0.5+ = 1-5 cells HPF; 1+ = 6-15 HPF; 2+ = 16-25 HPF; 3+ = 26-50 HPF; 4+ \>50.
COMPLETED
PHASE4
30 participants
Post-op Day 1
2025-08-17
Participant Flow
Contralateral eye study with randomization of one eye receiving a dexamethasone ophthalmic insert 0.4mg and the other eye receiving topical prednisolone acetate 1% four times daily for one week, three times daily for one week, two times daily for one eye, and then one time daily for one week.
60 eyes of 30 patients enrolled
Unit of analysis: Eyes
Participant milestones
| Measure |
Group A Dextenza Ophthalmic Insert 0.4mg
Randomized to dexamethasone ophthalmic insert 0.4mg placed prior to cataract surgery, on the day of surgery.
Dextenza 0.4Mg Ophthalmic Insert: The insert, containing 0.4 mg of active pharmaceutical product, is placed within the canaliculus to provide a sustained and tapered delivery of drug to the ocular surface over 30 days after a one-time insertion. The attributes of the insert reduce the risks for improper corticosteroid tapering and unwanted peaks and troughs in drug concentration.
|
Group B Topical Prednisolone Acetate 1%
Randomized to topical prednisolone acetate 1% four times per day for one week, three times per day for one week, two times per day for one week, and one time per day for one week starting after 4 hours after surgery.
Topical prednisolone acetate: Standard of care topical drop regimen with four week taper
|
|---|---|---|
|
Overall Study
STARTED
|
30 30
|
30 30
|
|
Overall Study
COMPLETED
|
30 30
|
30 30
|
|
Overall Study
NOT COMPLETED
|
0 0
|
0 0
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Race and Ethnicity were not collected from any participant.
Baseline characteristics by cohort
| Measure |
Group A Dextenza
n=30 Eyes
Randomized to dexamethasone ophthalmic insert 0.4mg placed prior to cataract surgery, on the day of surgery.
Dextenza 0.4Mg Ophthalmic Insert: The insert, containing 0.4 mg of active pharmaceutical product, is placed within the canaliculus to provide a sustained and tapered delivery of drug to the ocular surface over 30 days after a one-time insertion. The attributes of the insert reduce the risks for improper corticosteroid tapering and unwanted peaks and troughs in drug concentration.
|
Group B Topical Prednisolone
n=30 Eyes
Randomized to topical prednisolone acetate 1% four times per day for one week, three times per day for one week, two times per day for one week, and one time per day for one week starting after 4 hours after surgery.
Topical prednisolone acetate: Standard of care topical drop regimen with four week taper
|
Total
n=60 Eyes
Total of all reporting groups
|
|---|---|---|---|
|
Age, Continuous
|
67 years
STANDARD_DEVIATION 0.389 • n=30 Participants
|
67 years
STANDARD_DEVIATION 0.389 • n=30 Participants
|
67 years
STANDARD_DEVIATION 0.389 • n=60 Participants
|
|
Sex: Female, Male
Female
|
17 Participants
n=30 Participants
|
17 Participants
n=30 Participants
|
34 Participants
n=60 Participants
|
|
Sex: Female, Male
Male
|
13 Participants
n=30 Participants
|
13 Participants
n=30 Participants
|
26 Participants
n=60 Participants
|
|
Race and Ethnicity Not Collected
|
—
|
—
|
0 Participants
Race and Ethnicity were not collected from any participant.
|
|
Pain Score 0-10
|
2 units on a scale
n=30 Eyes
|
2 units on a scale
n=30 Eyes
|
2 units on a scale
n=60 Eyes
|
PRIMARY outcome
Timeframe: Post-op Day 1Population: Contralateral eye study of 30 patients. A total of 60 eyes analyzed with 30 eyes randomized to each group.
Mean anterior chamber cell/flare score measured by Slit Lamp Biomicroscopy evaluation using grading scale of 0 to 4 +. The scale used is called the (Standardization of Uveitis Nomenclature) SUN Working Group Grading Scheme. AC cell grading schema. The SUN Working Group defined their two AC grading schemas around these two findings. Importantly, for all grading schemas discussed in this article, an improvement in inflammation is a two-step decrease in grade. A worsening of inflammation occurs with a two-step increase in grade. Grade 0 = 0 cells per high power field or HPF; Grade 0.5+ = 1-5 cells HPF; 1+ = 6-15 HPF; 2+ = 16-25 HPF; 3+ = 26-50 HPF; 4+ \>50.
Outcome measures
| Measure |
Group A Dextenza
n=30 eyes
Randomized to dexamethasone ophthalmic insert 0.4mg placed prior to cataract surgery, on the day of surgery.
Dextenza 0.4Mg Ophthalmic Insert: The insert, containing 0.4 mg of active pharmaceutical product, is placed within the canaliculus to provide a sustained and tapered delivery of drug to the ocular surface over 30 days after a one-time insertion. The attributes of the insert reduce the risks for improper corticosteroid tapering and unwanted peaks and troughs in drug concentration.
|
Group B Topical Prednisolone
n=30 eyes
Randomized to topical prednisolone acetate 1% four times per day for one week, three times per day for one week, two times per day for one week, and one time per day for one week starting after 4 hours after surgery.
Topical prednisolone acetate: Standard of care topical drop regimen with four week taper
|
|---|---|---|
|
Mean Anterior Chamber Cell/Flare Score
|
1.06 Units on a scale
Interval 0.0 to 4.0
|
1.15 Units on a scale
Interval 0.0 to 4.0
|
PRIMARY outcome
Timeframe: Post-op Day 7Population: Contralateral eye study of 30 patients. A total of 60 eyes analyzed with 30 eyes randomized to each group.
Mean anterior chamber cell/flare score measured by Slit Lamp Biomicroscopy evaluation using grading scale of 0 to 4 +. The scale used is called the (Standardization of Uveitis Nomenclature) SUN Working Group Grading Scheme. AC cell grading schema. The SUN Working Group defined their two AC grading schemas around these two findings. Importantly, for all grading schemas discussed in this article, an improvement in inflammation is a two-step decrease in grade. A worsening of inflammation occurs with a two-step increase in grade. Grade 0 = 0 cells per high power field or HPF; Grade 0.5+ = 1-5 cells HPF; 1+ = 6-15 HPF; 2+ = 16-25 HPF; 3+ = 26-50 HPF; 4+ \>50. The higher the HPF, the more inflammation that can negatively impact a patient's outcome.
Outcome measures
| Measure |
Group A Dextenza
n=30 eyes
Randomized to dexamethasone ophthalmic insert 0.4mg placed prior to cataract surgery, on the day of surgery.
Dextenza 0.4Mg Ophthalmic Insert: The insert, containing 0.4 mg of active pharmaceutical product, is placed within the canaliculus to provide a sustained and tapered delivery of drug to the ocular surface over 30 days after a one-time insertion. The attributes of the insert reduce the risks for improper corticosteroid tapering and unwanted peaks and troughs in drug concentration.
|
Group B Topical Prednisolone
n=30 eyes
Randomized to topical prednisolone acetate 1% four times per day for one week, three times per day for one week, two times per day for one week, and one time per day for one week starting after 4 hours after surgery.
Topical prednisolone acetate: Standard of care topical drop regimen with four week taper
|
|---|---|---|
|
Mean Anterior Chamber Cell/Flare Score
|
0.25 score on a scale
Interval 0.0 to 4.0
|
0.22 score on a scale
Interval 0.0 to 4.0
|
PRIMARY outcome
Timeframe: post-op Week 4.Population: Contralateral eye study of 30 patients. A total of 60 eyes analyzed with 30 eyes randomized to each group.
Mean anterior chamber cell/flare score measured by Slit Lamp Biomicroscopy evaluation using grading scale of 0 to 4 +. The scale used is called the (Standardization of Uveitis Nomenclature) SUN Working Group Grading Scheme. AC cell grading schema. The SUN Working Group defined their two AC grading schemas around these two findings. Importantly, for all grading schemas discussed in this article, an improvement in inflammation is a two-step decrease in grade. A worsening of inflammation occurs with a two-step increase in grade. Grade 0 = 0 cells per high power field or HPF; Grade 0.5+ = 1-5 cells HPF; 1+ = 6-15 HPF; 2+ = 16-25 HPF; 3+ = 26-50 HPF; 4+ \>50. The higher the HPF, the more inflammation that can negatively impact a patient's outcome.
Outcome measures
| Measure |
Group A Dextenza
n=30 eyes
Randomized to dexamethasone ophthalmic insert 0.4mg placed prior to cataract surgery, on the day of surgery.
Dextenza 0.4Mg Ophthalmic Insert: The insert, containing 0.4 mg of active pharmaceutical product, is placed within the canaliculus to provide a sustained and tapered delivery of drug to the ocular surface over 30 days after a one-time insertion. The attributes of the insert reduce the risks for improper corticosteroid tapering and unwanted peaks and troughs in drug concentration.
|
Group B Topical Prednisolone
n=30 eyes
Randomized to topical prednisolone acetate 1% four times per day for one week, three times per day for one week, two times per day for one week, and one time per day for one week starting after 4 hours after surgery.
Topical prednisolone acetate: Standard of care topical drop regimen with four week taper
|
|---|---|---|
|
Number of Eyes With No Cell or Flare Measured
|
30 eyes
|
28 eyes
|
PRIMARY outcome
Timeframe: Post-op Day 1Mean pain score measured by Visual Analog Score numerical grading scale 0(minimum)-10(maximum) 0= absence of pain 10 = highest possible pain A higher number indicates a higher pain value which may impact a subject's outcomes.
Outcome measures
| Measure |
Group A Dextenza
n=30 Participants
Randomized to dexamethasone ophthalmic insert 0.4mg placed prior to cataract surgery, on the day of surgery.
Dextenza 0.4Mg Ophthalmic Insert: The insert, containing 0.4 mg of active pharmaceutical product, is placed within the canaliculus to provide a sustained and tapered delivery of drug to the ocular surface over 30 days after a one-time insertion. The attributes of the insert reduce the risks for improper corticosteroid tapering and unwanted peaks and troughs in drug concentration.
|
Group B Topical Prednisolone
n=30 Participants
Randomized to topical prednisolone acetate 1% four times per day for one week, three times per day for one week, two times per day for one week, and one time per day for one week starting after 4 hours after surgery.
Topical prednisolone acetate: Standard of care topical drop regimen with four week taper
|
|---|---|---|
|
Mean Pain Score
Pain score 0
|
23 Participants
|
23 Participants
|
|
Mean Pain Score
Pain score 1
|
2 Participants
|
2 Participants
|
|
Mean Pain Score
Pain score 2
|
2 Participants
|
3 Participants
|
|
Mean Pain Score
Pain score 3
|
2 Participants
|
2 Participants
|
|
Mean Pain Score
Pain score 4
|
1 Participants
|
0 Participants
|
PRIMARY outcome
Timeframe: Post-op Week 4Population: 30 patients in each cohort or 60 eyes
As measured by adapted COMTOL (Comparison of Ophthalmic Medications for Tolerability) Questionnaire. The COMTOL questionnaire is designed to assess the tolerability of topical ophthalmic medications. It consists of several elements that help evaluate the frequency, severity, and impact of common side effects: Section 1: Ocular Side Effects; Section 2: Local Side Effects; Section 3: Visual Function; Section 4: Impact on Quality of Life. Likert scale is used to measure each question. 1=Never, 2=Rarely, 3=Sometimes, 4 = Often, 5= Always. A higher score suggests that the medication is less well-tolerated and may be negatively impacting the patient's daily activities and overall well-being.
Outcome measures
| Measure |
Group A Dextenza
n=30 Participants
Randomized to dexamethasone ophthalmic insert 0.4mg placed prior to cataract surgery, on the day of surgery.
Dextenza 0.4Mg Ophthalmic Insert: The insert, containing 0.4 mg of active pharmaceutical product, is placed within the canaliculus to provide a sustained and tapered delivery of drug to the ocular surface over 30 days after a one-time insertion. The attributes of the insert reduce the risks for improper corticosteroid tapering and unwanted peaks and troughs in drug concentration.
|
Group B Topical Prednisolone
Randomized to topical prednisolone acetate 1% four times per day for one week, three times per day for one week, two times per day for one week, and one time per day for one week starting after 4 hours after surgery.
Topical prednisolone acetate: Standard of care topical drop regimen with four week taper
|
|---|---|---|
|
Patient Tolerability (Defined as Patient Preference)
No Preference
|
1 Participants
|
—
|
|
Patient Tolerability (Defined as Patient Preference)
Preferred Dexamethasone Inserts
|
29 Participants
|
—
|
|
Patient Tolerability (Defined as Patient Preference)
Preferred Preferred topical prednisolone acetate
|
0 Participants
|
—
|
SECONDARY outcome
Timeframe: postop Day 1Intraocular pressure as measured by Goldmann Applanation Tonometer; Total number of Participants with Increased IOP \>10mmHg above baseline. Normal intraocular pressure (IOP) is generally considered to be between 10 and 21 millimeters of mercury (mmHg). However, it's important to note that this is just a general range, and individual values can vary. A higher IOP may negatively impact a subject's outcome.
Outcome measures
| Measure |
Group A Dextenza
n=30 Participants
Randomized to dexamethasone ophthalmic insert 0.4mg placed prior to cataract surgery, on the day of surgery.
Dextenza 0.4Mg Ophthalmic Insert: The insert, containing 0.4 mg of active pharmaceutical product, is placed within the canaliculus to provide a sustained and tapered delivery of drug to the ocular surface over 30 days after a one-time insertion. The attributes of the insert reduce the risks for improper corticosteroid tapering and unwanted peaks and troughs in drug concentration.
|
Group B Topical Prednisolone
n=30 Participants
Randomized to topical prednisolone acetate 1% four times per day for one week, three times per day for one week, two times per day for one week, and one time per day for one week starting after 4 hours after surgery.
Topical prednisolone acetate: Standard of care topical drop regimen with four week taper
|
|---|---|---|
|
Number of Participants With Increased Intraocular Pressure (IOP) >10mmHg Above Baseline
|
1 Participants
|
0 Participants
|
SECONDARY outcome
Timeframe: Postop Day 7Intraocular pressure as measured by Goldmann Applanation Tonometer; Total number of Participants with Increased IOP \>10mmHg above baseline. Normal intraocular pressure (IOP) is generally considered to be between 10 and 21 millimeters of mercury (mmHg). However, it's important to note that this is just a general range, and individual values can vary. A higher IOP may negatively impact a subject's outcome.
Outcome measures
| Measure |
Group A Dextenza
n=30 Participants
Randomized to dexamethasone ophthalmic insert 0.4mg placed prior to cataract surgery, on the day of surgery.
Dextenza 0.4Mg Ophthalmic Insert: The insert, containing 0.4 mg of active pharmaceutical product, is placed within the canaliculus to provide a sustained and tapered delivery of drug to the ocular surface over 30 days after a one-time insertion. The attributes of the insert reduce the risks for improper corticosteroid tapering and unwanted peaks and troughs in drug concentration.
|
Group B Topical Prednisolone
n=30 Participants
Randomized to topical prednisolone acetate 1% four times per day for one week, three times per day for one week, two times per day for one week, and one time per day for one week starting after 4 hours after surgery.
Topical prednisolone acetate: Standard of care topical drop regimen with four week taper
|
|---|---|---|
|
Number of Participants With Increased Intraocular Pressure (IOP) >10mmHg Above Baseline
|
0 Participants
|
0 Participants
|
SECONDARY outcome
Timeframe: postop Week 4Intraocular Pressure as measured by Goldmann Applanation Tonometer, Total number of Participants with increased IOP \> 10mmHg above baseline. Normal intraocular pressure (IOP) is generally considered to be between 10 and 21 millimeters of mercury (mmHg). However, it's important to note that this is just a general range, and individual values can vary. A higher IOP may negatively impact a subject's outcome.
Outcome measures
| Measure |
Group A Dextenza
n=30 Participants
Randomized to dexamethasone ophthalmic insert 0.4mg placed prior to cataract surgery, on the day of surgery.
Dextenza 0.4Mg Ophthalmic Insert: The insert, containing 0.4 mg of active pharmaceutical product, is placed within the canaliculus to provide a sustained and tapered delivery of drug to the ocular surface over 30 days after a one-time insertion. The attributes of the insert reduce the risks for improper corticosteroid tapering and unwanted peaks and troughs in drug concentration.
|
Group B Topical Prednisolone
n=30 Participants
Randomized to topical prednisolone acetate 1% four times per day for one week, three times per day for one week, two times per day for one week, and one time per day for one week starting after 4 hours after surgery.
Topical prednisolone acetate: Standard of care topical drop regimen with four week taper
|
|---|---|---|
|
Number of Participants With Increased Intraocular Pressure (IOP) >10mmHg Above Baseline
|
0 Participants
|
0 Participants
|
SECONDARY outcome
Timeframe: post-op Week 4Cystoid Macular Edema (CME) as measured by optical coherence tomography (OCT); Total number of study participants with post-operative CME.
Outcome measures
| Measure |
Group A Dextenza
n=30 Participants
Randomized to dexamethasone ophthalmic insert 0.4mg placed prior to cataract surgery, on the day of surgery.
Dextenza 0.4Mg Ophthalmic Insert: The insert, containing 0.4 mg of active pharmaceutical product, is placed within the canaliculus to provide a sustained and tapered delivery of drug to the ocular surface over 30 days after a one-time insertion. The attributes of the insert reduce the risks for improper corticosteroid tapering and unwanted peaks and troughs in drug concentration.
|
Group B Topical Prednisolone
n=30 Participants
Randomized to topical prednisolone acetate 1% four times per day for one week, three times per day for one week, two times per day for one week, and one time per day for one week starting after 4 hours after surgery.
Topical prednisolone acetate: Standard of care topical drop regimen with four week taper
|
|---|---|---|
|
Number of Participants With Post-operative Cystoid Macular Edema (CME)
|
0 Participants
|
0 Participants
|
SECONDARY outcome
Timeframe: Day 0Population: Not applicable to Group B
Physician Ease of Use Survey following dexamethasone intracanalicular placement on Surgical Visit on Scale of 0-10 with 10 being most complex (0= minimum value or not complex and 10= maximum complexity). A higher number indicates a worse outcome.
Outcome measures
| Measure |
Group A Dextenza
n=30 Participants
Randomized to dexamethasone ophthalmic insert 0.4mg placed prior to cataract surgery, on the day of surgery.
Dextenza 0.4Mg Ophthalmic Insert: The insert, containing 0.4 mg of active pharmaceutical product, is placed within the canaliculus to provide a sustained and tapered delivery of drug to the ocular surface over 30 days after a one-time insertion. The attributes of the insert reduce the risks for improper corticosteroid tapering and unwanted peaks and troughs in drug concentration.
|
Group B Topical Prednisolone
Randomized to topical prednisolone acetate 1% four times per day for one week, three times per day for one week, two times per day for one week, and one time per day for one week starting after 4 hours after surgery.
Topical prednisolone acetate: Standard of care topical drop regimen with four week taper
|
|---|---|---|
|
Physician Ease of Use
|
3.9 Score on a scale
Interval 0.0 to 10.0
|
—
|
SECONDARY outcome
Timeframe: Post-op Day 7Population: 1 patient did not complete questionnaire. Patients were not asked to differentiate between eyes when answering the eye drop burden questionnaire
Eye Drop Burden Questionnaire numerical grading scale 8 questions on scale of 1-5 totaling a maximum score of 40. Likert scale used: 1 Very easy, 2. Easy 3. Neither easy nor difficult 4. Difficult 5. Very difficult Low Burden=8-18 Moderate Burden=19-29 High Burden= 30-40 A higher number score indicates a negative outcome for a subject.
Outcome measures
| Measure |
Group A Dextenza
n=29 Participants
Randomized to dexamethasone ophthalmic insert 0.4mg placed prior to cataract surgery, on the day of surgery.
Dextenza 0.4Mg Ophthalmic Insert: The insert, containing 0.4 mg of active pharmaceutical product, is placed within the canaliculus to provide a sustained and tapered delivery of drug to the ocular surface over 30 days after a one-time insertion. The attributes of the insert reduce the risks for improper corticosteroid tapering and unwanted peaks and troughs in drug concentration.
|
Group B Topical Prednisolone
Randomized to topical prednisolone acetate 1% four times per day for one week, three times per day for one week, two times per day for one week, and one time per day for one week starting after 4 hours after surgery.
Topical prednisolone acetate: Standard of care topical drop regimen with four week taper
|
|---|---|---|
|
Eye Drop Burden Reported by Participants
Low burden (maximum score between 8-18)
|
27 Participants
|
—
|
|
Eye Drop Burden Reported by Participants
Moderate burden (maximum score between 19-29)
|
2 Participants
|
—
|
|
Eye Drop Burden Reported by Participants
High burden (maximum score between 30-40)
|
0 Participants
|
—
|
SECONDARY outcome
Timeframe: post-op Week 4. Patients were not asked to differentiate between eyes when answering the eye drop burden questionnaireEye Drop Burden Questionnaire numerical grading scale 8 questions on scale of 1-5 totaling a maximum score of 40. Likert scale used: 1 Very easy, 2. Easy 3. Neither easy nor difficult 4. Difficult 5. Very difficult Low Burden=8-18 Moderate Burden=19-29 High Burden= 30-40 A higher score is considered a worse outcome for a subject.
Outcome measures
| Measure |
Group A Dextenza
n=30 Participants
Randomized to dexamethasone ophthalmic insert 0.4mg placed prior to cataract surgery, on the day of surgery.
Dextenza 0.4Mg Ophthalmic Insert: The insert, containing 0.4 mg of active pharmaceutical product, is placed within the canaliculus to provide a sustained and tapered delivery of drug to the ocular surface over 30 days after a one-time insertion. The attributes of the insert reduce the risks for improper corticosteroid tapering and unwanted peaks and troughs in drug concentration.
|
Group B Topical Prednisolone
Randomized to topical prednisolone acetate 1% four times per day for one week, three times per day for one week, two times per day for one week, and one time per day for one week starting after 4 hours after surgery.
Topical prednisolone acetate: Standard of care topical drop regimen with four week taper
|
|---|---|---|
|
Eye Drop Burden Reported by Participants
Low burden (maximum score between 8-18)
|
28 Participants
|
—
|
|
Eye Drop Burden Reported by Participants
Moderate burden (maximum score between 19-29)
|
2 Participants
|
—
|
|
Eye Drop Burden Reported by Participants
High burden (maximum score between 30-40)
|
0 Participants
|
—
|
Adverse Events
Group A Dextenza
Group B Topical Prednisolone
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place